Ophthalmic medical device company Sight Sciences, Inc. recently received full Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial comparing ab interno canaloplasty with Selective Laser Trabeculoplasty (SLT).
The VISCO™360 versus SLT Glaucoma Trial is reportedly multi-center, prospective, randomized, controlled clinical evaluation that will study the safety and effectiveness of the Sight Sciences VISCO360 Viscosurgical System in canaloplasty versus SLT in the reduction of intraocular pressure (IOP) in primary open angle glaucoma (POAG).
Photo courtesy Sight Sciences.
Click here to read the full press release.
Source: Sight Sciences, Inc.